Melanoma trial recruitment accelerating
22 March, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) has signed on 12 patients in the last three months for its phase II trial of oncolytic virus Cavatak in patients with late-stage melanoma.
Who’s who in biotech business development gather in Adelaide
21 March, 2013The Business Development Workshop and Forum has kicked off in Adelaide, with delegates keen to understand the changing landscape of licensing deal collaborations and what it means for business development in biotechnology companies.
iSonea unveils cloud asthma monitoring tool
20 March, 2013iSonea (ASX:ISN) has used an Asthma Foundation conference to unveil AsthmaSense Cloud, a system for cloud storage and transfer of wheeze monitoring data.
FDA rejects Pharmaxis’s NDA for Bronchitol
20 March, 2013 by Dylan Bushell-EmblingUS regulator FDA has told Pharmaxis (ASX:PXS) that it will likely need to conduct a new phase III trial before Bronchitol can be approved as a cystic fibrosis treatment.
Biotron HIV drug targets reservoir cells
20 March, 2013 by Dylan Bushell-EmblingPreliminary results of a phase Ib/IIa trial of Biotron’s BIT225 treatment candidate show it can target HIV in cells which mature into ongoing reservoirs for the virus.
Ondek names Jenny Harry CEO
19 March, 2013Ondek has appointed a new chief executive as it continues development of a drug delivery platform based on the research of its Nobel Laureate founder.
Comment invited on early warning system for medicines and medical devices
18 March, 2013The TGA and Medsafe are inviting comment on a consultation document for the trans-Tasman early warning system of safety concerns with medicines and medical devices.
FDA accepts QrxPharma’s revised MoxDuo NDA
15 March, 2013 by Dylan Bushell-EmblingThe US FDA will decide by 26 August whether to approve QRxPharma’s revised application for approval of its dual-opioid pain patch.
Hatchtech appoints Hugh Alsop CEO
13 March, 2013Hatchtech has appointed Australian pharmaceutical industry veteran Hugh Alsop to the post of CEO as it prepares for phase III trials of head lice treatment DeOvo.
Starpharma signs new agrochemical tie-up
13 March, 2013Starpharma (ASX:SPL) has signed a crop protection collaboration covering the use of its dendrimer nanotechnology platform technology by Makhteshim Agan.
Consultation opens for code of best practice
13 March, 2013Having undergone an expert review, The Code of Best Practice for Reporting by Life Sciences Companies is open for comment.
Pharmaxis names new CEO
13 March, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) COO Gary Phillips will replace founding CEO Alan Robertson at the helm and will re-examine the company’s business model in light of its expected FDA setback.
Alchemia raises $10.2m in placement
12 March, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has raised $10.2m in an institutional placement and will seek another $2m via an SPP to help fund its Phase III trial of HA-Irinotecan in colorectal cancer.
Special BIO rate for Australian delegation
12 March, 2013Companies that sign up to be part of the Australian Pavilion at BIO 2013 will receive a discounted registration rate for this biotech convention.
Positive results for new multiple myeloma treatment
11 March, 2013A new treatment for multiple myeloma, developed by Patrys, shows promising results in patients.
